Table 3.
Fabrication method |
PLA:PGA ratio |
Organic phase |
Surfactant | Mean diameter (nm) |
Encapsulation efficiency (%) |
Loaded drug amount (mg/mg) |
Release duration (days) |
Route of injection |
Reference |
---|---|---|---|---|---|---|---|---|---|
Multiple emulsion-solvent evaporation | 50:50 | DCM | PVA | 90.7–316.6 | 83.4 | 0.043 | 25 | - | 86 |
Multiple emulsion-solvent evaporation | 50:50 | DCM | Glycerin, span 60 | 67.2 | 63.8 | 0.073 | 35 | IV | 87 |
Emulsion-solvent evaporation | - | Aceto-nitrile | Span 80 | 800 | - | 0.20 | - | PT | 187 |
Nanoprecipitation | - | Liquid paraffin, aceto-nitrile | Span 80 | 200–1500 | - | - | - | - | 131 |
Abbreviations: SC – subcutaneous; IV – intravenous; DCM – dichloromethane; PLA – polylactic acid; PGA – polyglycolic acid; PT – peritumoral